Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform

About this update from Vanta Holdings Inc.

[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC0, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences company and parent of the Vanta premium longevity brand, announces a proposed non-brokered private placement financing (the "Private Placement"), consisting of the issuance of an aggregate of up to 2,500,000 units of the Company (each, a "Unit"), at a price of $1.00 per Unit for aggregate gross proceeds of up to $2,500,000.","length":533,"tagName":"p"},{"type":"text","content":"Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one transferable common share purchase warrant of the Company (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Share (each, a "Warrant Share") at a price of $1.25 per Warrant Share for a period of 24 months from the date of closing.","length":394,"tagName":"p"},{"type":"text","content":"Closing of the Private Placement is anticipated to occur on or about June 30, 2026, and may be completed in one or more tranches, subject to compliance with the policies of the Canadian Securities Exchange.","length":206,"tagName":"p"},{"type":"text","content":"The net proceeds of the Private Placement are intended to be allocated towards advancing the Company's integrated longevity and consumer health sciences platform, including, without limitation, its planned entry into the U.S. peptide market, product commercialization efforts, business development activities, the payment of outstanding payables and indebtedness, corporate awareness initiatives, and general working capital purposes. The securities issued under the Private Placement will be subject to a statutory hold period expiring four months and one day from the date of issuance.","length":591,"tagName":"p"},{"type":"text","content":"Insiders may participate in the Private Placement, and such participation may constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI61-101"). The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under subsections 5.5(a) and 5.7(a) of MI 61-101 on th...

More updates from Vanta Holdings Inc.